Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17

British Journal of Pharmacology

Volumn 154, Issue 4, 2008, Pages 825-832

  Requena, P ^a   Daddaoua, A ^a   Martinez Plata E ^a   Gonzalez M ^a   Zarzuelo, A ^a   Suarez M D ^a,b   Sanchez De Medina F ^a   Martinez Augustin O ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Experimental ileitis; Glycomacropeptide; Inflammatory bowel disease; Interleukin 1; Interleukin 17; Regulatory T cells; Trinitrobenzenesulphonic acid

Indexed keywords

ALKALINE PHOSPHATASE; BOVINE GLYCOMACROPEPTIDE; GAMMA INTERFERON; GLYCOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; MESALAZINE; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; FEMALE; ILEITIS; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT GAIN; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CATTLE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GLYCOPEPTIDES; ILEITIS; INTERLEUKIN-17; MACROPHAGES; MESALAMINE; RATS; RATS, WISTAR; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TRINITROBENZENESULFONIC ACID;

EID: 45249108440     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.138     Document Type: Article

References (40)

1. Aimutis WR (2004). Bioactive properties of milk proteins with particular focus on anticariogenesis. J Nutr 134: 989S-995S.
2. Alexander F (2007). Complications of ileal pouch anal anastomosis. Semin Pediatr Surg 16: 200-204.
3. Bamias G, Martin C, Mishina M, Ross WG, Rivera-Nieves J, Marini M et al. (2005). Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 128: 654-666.
4. Bamias G, Okazawa A, Rivera-Nieves J, Arseneau KO, De La Rue SA, Pizarro TT et al. (2007). Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J Immunol 178: 1809-1818.
5. Baumgart DC, Carding SR (2007). Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640.
6. Baumgart DC, Sandborn WJ (2007). Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
7. Bettelli E, Korn T, Kuchroo VK (2007). Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 19: 652-657.
8. Bounous G, Kongshavn PA (1985). Differential effect of dietary protein type on the B-cell and T-cell immune responses in mice. J Nutr 115: 1403-1408.
9. Brody EP (2000). Biological activities of bovine glycomacropeptide. Br J Nutr 84: S39-S46.
10. Bruck WM, Kelleher SL, Gibson GR, Nielsen KE, Chatterton DEW, Lonnerdal B (2003). rRna probes used to quantify the effects of glycomacropeptide and alpha-lactalbumin supplementation on the predominant groups of intestinal bacteria of infant Rhesus monkeys challenged with enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr 37: 273-280.
11. Bruck WM, Redgrave M, Tuohy KM, Lonnerdal B, Graverholt G, Hernell O et al. (2006). Effects of bovine alpha-lactalbumin and casein glycomacropeptide-enriched infant formulae on faecal microbiota in healthy term infants. J Pediatr Gastroenterol Nutr 43: 673-679.
12. Chabance B, Jolles P, Izquierdo C, Mazoyer E, Francoual C, Drouet L et al. (1995). Characterization of an antithrombotic peptide from kappa-casein in newborn plasma after milk ingestion. Br J Nutr 73: 583-590.
13. Chabance B, Marteau P, Rambaud JC, Migliore-Samour D, Boynard M, Perrotin P et al. (1998). Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochimie 80: 155-165.
14. Daddaoua A, Puerta V, Zarzuelo A, Suarez MD, Sanchez de Medina F, Martinez-Augustin O (2005). Bovine glycomacropeptide is antiinflammatory in rats with hapten-induced colitis. J Nutr 135: 1164-1170.
15. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O et al. (1997). Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 113: 118-126.
16. Dohi T, Fujihashi K, Koga T, Shirai Y, Kawamura YI, Ejima C et al. (2003). T helper type-2 cells induce ileal villus atrophy, goblet cell metaplasia, and wasting disease in T cell-deficient mice. Gastroenterology 124: 672-682.
17. Fantini MC, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF et al. (2007). IL-21 regulates experimental colitis by modulating the balance between T(reg) and Th17 cells. Eur J Immunol 37: 3155-3163.
18. Gottlieb AB (2007). Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc 12: 1-4.
19. Idota T, Kawakami H, Nakajima I (1994). Growth-promoting effects of N-acetylneuraminic acid-containing substances on Bifidobacteria. Biosci Biotech Biochem 58: 1720-1722.
20. Izcue A, Coombes JL, Powrie F (2006). Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 212: 256-271.
21. Krawisz JE, Sharon P, Stenson WF (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350.
22. Li EW, Mine Y (2004). Immunoenhancing effects of bovine glycomacropeptide and its derivatives on the proliferative response and phagocytic activities of human macrophagelike cells, U937. J Agric Food Chem 52: 2704-2708.
23. Madureira AR, Pereira CI, Gomes AMP, Pintado ME, Malcata FX (2007). Bovine whey proteins - overview on their main biological properties. Food Res Intern 40: 1197-1211.
24. Mikkelsen TL, Rasmussen E, Olsen A, Barkholt V, Frokiaer H (2006). Immunogenicity of kappa-casein and glycomacropeptide. J Dairy Sci 89: 824-830.
25. Monnai M, Horimoto Y, Otani H (1998). Immunomodificatory effect of dietary bovine kappa-caseinoglycopeptide on serum antibody levels and proliferative responses of lymphocytes in mice. Milchwissenschaft 53: 129-132.
26. Monnai M, Otani H (1997). Effect of bovine k-caseinoglycopeptide on secretion of interleukin-1 family cytokines by P388D1 cells, a line derived from mouse monocyte/macrophage. Milchwissenschaft 52: 192-196.
27. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795-803.
28. Nakai S, Modler HW (1999). Food Proteins. Processsing applications. Wiley-VCH Inc.: New York.
29. Navarro-Llavat M, Domenech E, Masnou H, Ojanguren I, Manosa M, Lorenzo-Zuniga V et al. (2007). Collagenous duodeno-ileo-colitis with transient IgG deficiency preceded by Yersinia enterocolitica intestinal infection: case report and review of literature. Gastroenterol Hepatol 30: 219-221.
30. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R et al. (2007). Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13: 1323-1332.
31. Neurath MF (2007). IL-23: a master regulator in Crohn disease. Nat Med 13: 26-28.
32. Ochs HD, Gambineri E, Torgerson TR (2007). IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 38: 112-121.
33. Otani H, Horimoto Y, Monnai M (1996). Suppression of interleukin-2 receptor expression on mouse CD4+ T cells by bovine kappa-caseinoglycopeptide. Biosci Biotechnol Biochem 60: 1017-1019.
34. Otani H, Monnai M, Kawasaki Y, Kawakami H, Tanimoto M (1995). Inhibition of mitogen-induced proliferative responses of lymphocytes by bovine kappa-caseinoglycopeptides having different carbohydrate chains. J Dairy Res 62: 349-357.
35. Sanchez de Medina F, Martinez-Augustin O, Gonzalez R, Ballester I, Nieto A, Galvez J et al. (2004). Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease. Biochem Pharmacol 68: 2317-2326.
36. Sands BE (2004). From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 126: 1518-1532.
37. Sands BE (2007). Inflammatory bowel disease: past, present, and future. J Gastroenterol 42: 16-25.
38. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007). IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852.
39. Yakabe T, Kawakami H, Idota T (1994). Growth stimulation agent for bifidus and lactobacillus. Japanese patent 07-267866.
40. Zimecki M, Artym J, Chodaczek G, Kocieba M, Rybka J, Skorska A et al. (2006). Glycomacropeptide protects against endotoxemia and bacteremia in mice. Electr J Polish Agricult Univ 9 (online).